BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen QF, Wu PH, Huang T, Shen LJ, Huang ZL, Li W. Efficacy of treatment regimens for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019;98:e17460. [PMID: 31577775 DOI: 10.1097/md.0000000000017460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen QF, Shi F, Huang T, Huang C, Shen L, Wu P, Li W. ASTN1 is associated with immune infiltrates in hepatocellular carcinoma, and inhibits the migratory and invasive capacity of liver cancer via the Wnt/β‑catenin signaling pathway. Oncol Rep 2020;44:1425-40. [PMID: 32945491 DOI: 10.3892/or.2020.7704] [Reference Citation Analysis]
2 Zhou G, Li Y, Li S, Liu H, Xu F, Lai X, Zhang Q, Xu J, Wan S. Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine. Front Genet 2021;12:719451. [PMID: 34603382 DOI: 10.3389/fgene.2021.719451] [Reference Citation Analysis]
3 Wang L, Ke J, Wang C, Li Y, Wu G, Ding Q, Luo Q, Cai R, Lv P, Song T, Xiong S. Efficacy and Safety of Banxia XieXin Decoction, a Blended Traditional Chinese Medicine, as Monotherapy for Patients With Advanced Hepatocellular Carcinoma. Integr Cancer Ther 2020;19:1534735420942587. [PMID: 32787468 DOI: 10.1177/1534735420942587] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Al Mahtab M, Rahim MA, Noor-E-Alam SM, Alam MA, Khondaker FA, Moben AL, Ghosh J, Khan MSI. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepatogastroenterol 2019;9:63-6. [PMID: 32117692 DOI: 10.5005/jp-journals-10018-1300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Su D, Wu B, Shi L. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e210037. [PMID: 33625508 DOI: 10.1001/jamanetworkopen.2021.0037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
7 Hou Y, Wu B. Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis. Cancer Commun (Lond) 2020;40:743-5. [PMID: 33159490 DOI: 10.1002/cac2.12110] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]